SEC Form 4 · accession 0001140361-15-041198

Emergent BioSolutions Inc. · EBS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP, Biosciences Div.

Period of report

Nov 11, 2015

Accepted (ET)

Nov 13, 2015 · 4:49 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001367644

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F4	Nov 11, 2015	S	6,564	$35.51	D	30,229	D
Common Stock^F1	Nov 11, 2015	M	9,373	$28.09	A	39,602	D
Common Stock^F1	Nov 11, 2015	S	9,373	$35.50	D	30,229	D
Common Stock^F2	Nov 11, 2015	M	10,095	$20.94	A	40,324	D
Common Stock^F2,F4	Nov 11, 2015	S	10,095	$35.50	D	30,229	D
Common Stock^F2	Nov 12, 2015	M	10,094	$20.94	A	40,323	D
Common Stock^F2	Nov 12, 2015	S	10,094	$36.00	D	30,229	D
Common Stock^F3	Nov 11, 2015	F	1,671	$35.88	D	28,558	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Stock Option^F1	$28.09	Nov 11, 2015	M	9,373	D	Mar 11, 2014	Mar 10, 2021	Common Stock	9,373	D
Stock Option^F2	$20.94	Nov 11, 2015	M	10,095	D	Nov 11, 2013	Nov 11, 2020	Common Stock	10,095	D
Stock Option^F2	$20.94	Nov 12, 2015	M	10,094	D	Nov 11, 2013	Nov 11, 2020	Common Stock	10,094	D

F1Consists of an option granted under the company's stock incentive plan on March 11, 2014.
F2Consists of an option granted under the company's stock incentive plan on November 12, 2013.
F3Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended.
F4The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.50-$35.59, inclusive.